Alivus Life Sciences Announces 15th AGM on Sep 8, 2026, with ₹5 Dividend
Alivus Life Sciences will hold its 15th AGM on September 8, 2026, via VC/OAVM. The company proposes a final dividend of ₹5 per equity share for FY26. Mr. Hiren Patel's re-appointment as director and ratification of cost auditor remuneration are also on the agenda. E-voting is open from Sep 4-7, 2026.
The AGM is a significant event for shareholders, involving important decisions like dividend approval and director appointments. The details provided are material for investor awareness.
The announcement is a routine corporate event (AGM) and includes standard financial reporting and dividend declaration. While the dividend is a positive factor, the overall nature of the announcement is informational and procedural.
Alivus Life Sciences Limited has announced its 15th Annual General Meeting (AGM) for the Financial Year 2025-26, scheduled to be held on Tuesday, September 8, 2026, at 3:00 PM IST. The meeting will be conducted through Video Conferencing (VC) / Other Audio-Visual Means (OAVM).
Key agenda items for the AGM include the adoption of Audited Financial Statements for the Financial Year ended March 31, 2026, and the declaration of a final dividend of ₹5 per equity share of face value ₹2. Additionally, Mr. Hiren Patel will be re-appointed as a Non-Executive Director retiring by rotation. The remuneration of the Cost Auditors, Kirit Mehta & Co. LLP, for the financial year ending March 31, 2027, is also proposed for ratification at ₹0.50 million plus applicable taxes and expenses.
The notice of the AGM has been sent to all registered members. Shareholders whose names appear in the register of members or beneficial owners as of the cut-off date, Tuesday, September 1, 2026, are eligible to vote. The remote e-voting facility will commence on Friday, September 4, 2026, at 9:00 AM IST and conclude on Monday, September 7, 2026, at 5:00 PM IST.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.